ixazomib proteasome inhibitor
"
이카조미브 시트라트 (1201902-80-8)
Ixazomib Citrate (1201902-80-8) Ixazomib citrate is a proteasome inhibitor that prevents cell growth in solid tumours. This anti-cancer agent is specifically used for the treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate demonstrates superior pharmacokinetics, efficacy, and anticancer activity. Key Features Proteasome inhibitor for cancer treatment Specifically indicated for multiple myeloma Superior pharmacokinetics compared to bortezomib Enhanced
(αR) -(1S,2S,3R,5S) -피나나디올-1-아미노-3-메틸부탄-1-보론트 트리플루오아세테트 (179324-87-9)
(αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) is a specialized chemical compound used in the design and preparation of pharmaceutical agents including Ixazomib and Bortezomib. Product Specifications Product Name: (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate CAS No.: 179324-87-9 Assay: 98% End Use:
